Health Care, Patient Service was bioAffinity Technologies’s largest product and service line in fiscal 2025, bringing in $9.94M of $12.33M (81%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Health Care, Patient Service | — | $4.47M | $16.35M | $9.94M |
| Histology Service Fees | — | $545.32K | $2.21M | $2.23M |
| Medical Director Fees | — | $38.65K | $133.15K | $136.54K |
| Other Revenues | $9.61K | $43.03K | $14.74K | $9.72K |
| Diagnostic Research & Development | — | — | $17.31K | $1.15K |
| Diagnostic Rd | — | $38.88K | — | — |
| Department Of Defense Observational Studies | — | $38.88K | $17.31K | $1.15K |
| Laboratory Services | $9.61K | — | — | — |
| Total | $19.21K | $5.17M | $18.74M | $12.33M |
bioAffinity Technologies brought in $12.33M from its six product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 34.2% from $18.74M in fiscal 2024. Health Care, Patient Service was the largest at $9.94M (80.7%), ahead of Histology Service Fees at $2.23M (18.1%) and Medical Director Fees at $136.54K (1.1%). The other three lines brought in $12.03K combined.
Compared with fiscal 2024, Histology Service Fees grew 1.2% to $2.23M, while Health Care, Patient Service fell 39.2% to $9.94M.
bioAffinity Technologies began breaking out Health Care, Patient Service in fiscal 2023, Histology Service Fees in fiscal 2023, Medical Director Fees in fiscal 2023 and Diagnostic Research & Development in fiscal 2024. bioAffinity Technologies stopped reporting Diagnostic Rd ($38.88K in fiscal 2023) and Laboratory Services ($9.61K in fiscal 2022) as separate lines.
bioAffinity Technologies (BIAF) reports its revenue by product and service. In fiscal 2025, Health Care, Patient Service was its largest product and service line, bringing in $9.94M (80.7% of the total), followed by Histology Service Fees at $2.23M (18.1%).
Health Care, Patient Service was bioAffinity Technologies' largest product and service line in fiscal 2025, bringing in $9.94M, or 80.7% of the $12.33M total across its six product and service lines.
Histology Service Fees grew faster than Health Care, Patient Service in fiscal 2025, up 1.2% from $2.21M to $2.23M. Health Care, Patient Service fell 39.2% to $9.94M.
Every figure comes from bioAffinity Technologies' annual financial filings, as reported. Each line keeps the name bioAffinity Technologies gives it, and years follow its fiscal calendar.
bioAffinity Technologies' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.